The purpose of this study is to compare the usual chemo-immunotherapy treatment for triple negative breast cancer to a shorter chemo-immunotherapy treatment that uses fewer drugs.
Learn more about the S2212/SCARLET trial or call the Cancer Research Office at Reading Hospital 484-628-8193.
